US Cases/Year
~19,700
5th leading cause of cancer death in women; ~13,000 deaths/year.[1]
What Is It
Definition, mechanism, and the clinical reality of ovarian cancer at end of life. What the hospice team needs to understand on day one.
Stage III–IV at Dx
~75%
Defines why prognosis is so poor — most disease is advanced by the time of diagnosis.[1]
5-Year Survival III–IV
~29%
Stage III: ~42%; Stage IV: ~17%. BRCA-mutant patients have somewhat better outcomes due to platinum and PARP sensitivity.[37]
Platinum-Resistance Rate
~25%→70%
~25% are primary platinum-resistant; ~70% eventually develop platinum resistance over the disease course.[37]
Ovarian cancer is primarily a disease of the peritoneal cavity. High-grade serous ovarian cancer — the most common and most lethal subtype — disseminates early and widely across peritoneal surfaces, bowel mesentery, and the omentum. By the time most patients present with symptoms (abdominal bloating, pelvic pain, early satiety, urinary frequency), disease is already Stage III or IV. This biological reality — diffuse peritoneal spread before diagnosis — is why surgery and chemotherapy, even when initially successful, so rarely produce durable cure.[1]
At end of life, the peritoneal cavity becomes the primary battlefield. Malignant ascites distends the abdomen, compresses the diaphragm, causes nausea and early satiety, and prevents comfortable positioning. Malignant bowel obstruction (MBO) occurs in 10–50% of advanced cases — often multifocal, extrinsic, and not surgically correctable. Peritoneal carcinomatosis pain is diffuse, constant, and difficult to localize. Pleural effusions develop. Fatigue and cachexia progress. By hospice enrollment, the patient has typically endured multiple chemotherapy regimens, one or more surgical debulkings, and the relentless cycle of partial response followed by progression — often over 3–7 years.[40]
🧭 Clinical Framing
Ovarian cancer does not just kill the body — it dismantles it section by section. The belly distends. The bowel stops. The lungs fill. By hospice enrollment, this patient has been through more cycles of hope and loss than almost any other cancer diagnosis. The clinical team's job is to stay ahead of all of it, in the right order, with the right urgency. You can't treat this disease gently. You have to be present and aggressive about comfort — because the moment you fall behind, the suffering compounds faster than any other cancer I've seen in 12 years.
"Ovarian cancer doesn't just kill the body — it dismantles it section by section. The belly distends. The bowel stops. The lungs fill. Our job is to stay ahead of all of it, in the right order, with the right urgency. You can't treat this disease gently. You have to be present and aggressive about comfort — because the moment you fall behind, the suffering compounds faster than any other cancer I've seen in 12 years."
— Waldo, NP · Terminal2
How It's Diagnosed
Diagnostic workup, staging, molecular profile, and what to extract from hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Diagnostic Workup
- Transvaginal ultrasound: First-line imaging for pelvic mass evaluation; characterizes morphology (solid vs. cystic, septations, vascularity)
- CT/PET staging: CT chest/abdomen/pelvis to assess extent of peritoneal spread, lymphadenopathy, pleural effusion; PET for metabolically active sites
- CA-125: Tumor marker — elevated in ~80% of epithelial ovarian cancer, but non-specific (elevated in endometriosis, fibroids, PID). Used for monitoring disease trajectory, not diagnosis. Rapidly rising CA-125 = accelerating disease
- Surgical staging: Ovarian cancer is surgically staged (FIGO) — staging happens in the OR, not on imaging. Surgical pathology report is the definitive source
- Histology: High-grade serous (HGSC) most common (~70%) and most aggressive; clear cell (platinum-resistant, younger patients); endometrioid (endometriosis-associated); mucinous (rare, earlier stage); low-grade serous (slow-growing, MEK-pathway)
- Molecular testing: BRCA1/2 germline and somatic (for PARP inhibitor eligibility); HRD (homologous recombination deficiency); MSI/MMR status (for pembrolizumab in MSI-H rare cases)
What to Look for in Hospice Records
- BRCA1/2 status: Germline mutations affect daughters, sisters, and sons — genetic counseling referral remains a clinical obligation even at hospice enrollment. Document and flag for family
- Prior debulking surgery and residual disease: Optimal debulking (<1 cm residual) vs. suboptimal — shapes trajectory and prior chemotherapy sensitivity
- Platinum sensitivity classification: Sensitive (PFI >6 months), resistant (PFI <6 months), refractory (progression on platinum) — the single most important prognostic datapoint in your chart review
- CA-125 trend: Rapidly rising = accelerating disease burden; note the rate of change, not just the number
- Prior PARP inhibitor use: Olaparib, niraparib, rucaparib — know if received and when stopped; affects remaining treatment options
- Ascites history: First paracentesis date and current frequency — increasing frequency is the prognostic clock (q10 days or less = final weeks)
- Bowel surgery history: Prior bowel resections, stomas, adhesions — affects MBO risk, surgical candidacy, and tube feeding planning
💡 For Families
Ovarian cancer is usually found when it has already spread inside the belly. By the time symptoms appeared — bloating, abdominal pressure, changes in eating — the cancer had often been growing silently for months or years. This is not because anyone missed something; it is the nature of this disease. The focus now is entirely on keeping your loved one comfortable, managing symptoms, and being present. The diagnostic testing phase is over. We are in the comfort phase.
Causes & Risk Factors
Hereditary and modifiable risk factors. Relevant for family conversations, genetic counseling referrals, and answering "why did this happen?"
Risk Factors
- Age: Incidence peaks at 55–64; most common in postmenopausal women
- BRCA1 mutation: 39–46% lifetime risk of ovarian cancer (vs. 1.4% population risk)
- BRCA2 mutation: 10–27% lifetime risk
- Lynch syndrome (MLH1/MSH2/MSH6/PMS2): 10–12% lifetime risk; associated with endometrioid and clear cell subtypes
- Nulliparity: Never having been pregnant increases risk — each pregnancy reduces lifetime ovulation cycles
- Early menarche / late menopause: More lifetime ovulations = higher risk
- Endometriosis: 3–8× risk for clear cell and endometrioid subtypes specifically
- Hormone replacement therapy: Estrogen-only HRT (post-hysterectomy) associated with modestly increased risk
- Talc use: Perineal talc application — association reported but remains controversial and under study
- Obesity: Modest association; BMI >30 increases risk ~25–30%
Protective Factors
- Oral contraceptive pills: 40–50% lifetime risk reduction with >5 years of use — one of the strongest known protective factors for any cancer. Each year of OCP use reduces risk ~5%
- Breastfeeding: Modest protective effect; each month reduces risk ~2%
- Tubal ligation: ~65% risk reduction for HGSC; mechanism uncertain (possible prevention of ascending carcinogenic exposure)
- Salpingo-oophorectomy (BSO) in BRCA carriers: Risk-reducing BSO at age 35–40 reduces ovarian cancer risk by >80% and reduces breast cancer risk by 50% if premenopausal
- Multiparity: Each pregnancy reduces risk modestly; four or more pregnancies approximately halves baseline risk
❤️ For Families: "Why Did This Happen?"
Families ask this question — and they deserve a direct, compassionate answer. Ovarian cancer is not caused by anything your loved one did wrong. In most cases, it arises from a combination of genetic factors, lifetime ovulation patterns, and biological processes that are not preventable through diet, lifestyle, or screening. If BRCA1 or BRCA2 mutations are present, that is important information for daughters, sisters, and sons — genetic counseling can save lives in surviving family members. This is not a burden to carry. It is information that creates opportunity for protection.
⚕ Clinician Note: Disparities in Ovarian Cancer
White women have a higher incidence of ovarian cancer. Black women have a significantly worse survival — not because of disease biology, but because of disparities in access to high-volume surgical centers, enrollment in clinical trials, receipt of guideline-concordant chemotherapy, and hospice utilization. If your patient is Black and has a BRCA mutation identified, ensure that surviving family members receive an explicit, documented referral for genetic counseling. Do not rely on the oncology team to have done this — verify it is in place.
🧬 BRCA Germline Counseling at Hospice Enrollment
Even when a patient is actively dying, BRCA1/2 germline status is actionable for surviving family members. Daughters of a BRCA1 carrier have a 50% chance of carrying the mutation — and a >40% lifetime risk of ovarian cancer if they do. At hospice enrollment: document BRCA status in your chart, ask if the patient has shared this information with adult children, and offer a referral for the family to genetic counseling resources. This is a clinical obligation, not an afterthought.
Treatments & Procedures
Disease-directed therapy trajectory and palliative procedures. Understanding what this patient has been through helps anticipate what comes next.
The typical hospice patient with ovarian cancer has been in treatment for 3–7 years. She has received first-line carboplatin/paclitaxel (often with bevacizumab), undergone one or more surgical debulkings, and — if BRCA-mutant or HRD-positive — received maintenance PARP inhibitor therapy. After first recurrence, she received one or more platinum-based re-treatment regimens. After developing platinum resistance, she received non-platinum single agents: liposomal doxorubicin, gemcitabine, topotecan, weekly paclitaxel, or bevacizumab combinations. By the time she enrolls in hospice, she has typically progressed through 3–6 lines of therapy, and her performance status has declined to the point where further chemotherapy offers more toxicity than benefit.[37]
Disease-Directed Therapy
- Primary debulking surgery (PDS): Cytoreduction to <1 cm residual disease at diagnosis; determines initial prognosis. Interval debulking surgery (IDS) after neoadjuvant chemo for patients not surgically optimal upfront. Secondary debulking in selected platinum-sensitive recurrence
- First-line chemotherapy: Carboplatin AUC5–6 + paclitaxel 175 mg/m² q3wk × 6 cycles. Bevacizumab may be added (GOG-0218/ICON7) in high-risk disease. IP chemotherapy (GOG-172) in optimally debulked Stage III
- PARP inhibitors (maintenance): Olaparib (BRCA-mutant), niraparib (all-comers, PRIMA), rucaparib (BRCA-mutant or HRD+). Significantly extend PFS in platinum-sensitive disease after response. Know if patient received PARP and when stopped
- Platinum-resistant regimens: Liposomal doxorubicin (Doxil) 50 mg/m² q4wk; gemcitabine 1000 mg/m² days 1+8 q3wk; topotecan 1.5 mg/m² days 1–5 q3wk; weekly paclitaxel 80 mg/m²; bevacizumab ± chemotherapy
- Immunotherapy: Pembrolizumab for MSI-H/dMMR ovarian cancer (rare, ~2–3% of cases); meaningful responses in this rare subset
Palliative Procedures
- Paracentesis (large-volume): Standard of care for malignant ascites; 4–6L safely drained without albumin replacement needed; outpatient/same-day compatible; hospice-appropriate. Frequency is a prognostic clock[2]
- Indwelling peritoneal catheter (IPC/PleurX): Transforms ascites management for patients requiring paracentesis >q2wk; 1–2L drained at home every 1–3 days; family can be trained; dramatically improves QoL and reduces hospitalizations[15]
- Venting gastrostomy (PEG-V): For MBO — provides decompression, not feeding; allows comfort sips while venting gastric contents; 92% reduction in nausea/vomiting reported; hospice-compatible when survival expected weeks to months[24]
- Thoracentesis / pleural IPC: For symptomatic malignant pleural effusions; indwelling pleural catheter for recurrent effusions in patients with life expectancy >1 month
- Celiac plexus neurolysis: For refractory upper abdominal carcinomatosis pain; reduces opioid requirements; hospice-compatible in appropriate candidates[27]
When Therapy Makes Sense
Evidence-based criteria for continuing disease-directed therapy. Not about giving up or holding on — it's about reading the data correctly.
Davidson et al. demonstrated that systematic identification of patients with platinum-resistant or recurrent gynecologic cancer — combined with provider pre-encounter alerts — increased timely goals-of-care documentation from 30% to 89%, and significantly reduced chemotherapy use in the last 14 days of life without reducing survival.[38] The implication is clear: timely, honest, proactive conversations about disease trajectory produce better care outcomes than avoidance. But those conversations require knowing when the data genuinely support continued treatment — and when it does not.
- 01Platinum-sensitive relapse (PFI >6 months) with ECOG 0–2: Re-treatment with platinum-based regimen offers meaningful OS benefit. Median OS from platinum-sensitive recurrence is 18–36 months with appropriate therapy. This is the most evidence-supported indication for continued disease-directed therapy at recurrence.[37]
- 02BRCA-mutant platinum-sensitive relapse — PARP inhibitor maintenance: Olaparib, niraparib, or rucaparib maintenance after platinum-sensitive response significantly extends PFS (SOLO-2, NOVA, ARIEL3 trials). Oral administration; toxicity manageable in ECOG 0–1. Extend meaningful survival in this population.[37]
- 03Bevacizumab in platinum-sensitive relapse: OCEANS and GOG-0213 trials show modest PFS benefit; may reduce ascites reaccumulation rate through anti-VEGF mechanism — an ascites-specific rationale for use in selected patients still seeking active therapy.[8]
- 04Single-agent chemotherapy in platinum-resistant ECOG 0–1: Response rates 10–20%; may reduce symptom burden (particularly ascites) and provide modest OS benefit. Acceptable when patient is well-informed, goals include life prolongation, and performance status supports treatment tolerance.
- 05MSI-H/dMMR ovarian cancer with pembrolizumab: Rare (2–3% of cases) but clinically meaningful — pembrolizumab produces durable responses in MSI-H solid tumors regardless of histology. Worth identifying in chart review if not previously tested.
- 06Patient goals explicitly include life-prolongation with full prognosis understanding: A well-informed patient who understands her prognosis and chooses continued active treatment deserves it without judgment. The key word is "well-informed" — ensure the platinum-sensitivity conversation has been had explicitly and plainly.
📋 Clinician Note: The Platinum-Sensitivity Conversation
The platinum-sensitivity classification — sensitive vs. resistant vs. refractory — is the single most important prognostic framework in ovarian cancer and the most important conversation the hospice NP often has to initiate. Most oncologists soften it. They don't lie — but they don't say it plain. Someone has to say: "The chemotherapy has stopped working the way we need it to, and the side effects are now bigger than the benefit." That is the hospice NP's moment. Say it.
When It Doesn't
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
In the EOLO study, 38% of ovarian cancer patients received chemotherapy in the final month of life — and only 4.5% died in hospice.[40] This is not a patient preference problem. It is a systems failure driven by delayed hospice conversations, inadequate prognostic disclosure, and the relentless framing of further chemotherapy as "trying something." The hospice NP's role is to close this gap — specifically, to name the moment when further disease-directed therapy stops being reasonable and starts being harmful.
- 01Platinum-refractory disease (progression on platinum): No benefit from further platinum-based therapy. Median OS 3–6 months. Non-platinum alternatives have response rates <20% and do not change the trajectory meaningfully at this point. This is the clearest hospice referral threshold.[37]
- 02Progression through ≥3 lines of chemotherapy: Response rates to 4th and 5th line regimens are <10%. Toxicity dominates benefit. The patient is experiencing the treatment, not the disease. At this point, the clinical obligation is to say so plainly.
- 03ECOG performance status ≥3: No evidence of chemotherapy benefit at ECOG ≥3 in ovarian cancer. The body cannot tolerate cytotoxic therapy. Treatment in this population produces toxicity without meaningful response.[40]
- 04Malignant bowel obstruction with peritoneal carcinomatosis: Surgery carries 20–40% perioperative mortality in this population — and the majority who survive do not have resolution of obstruction.[20] Medical management (octreotide, dexamethasone, haloperidol, venting gastrostomy) is the answer. Surgery is not.
- 05Ascites requiring paracentesis more frequently than every 2 weeks: This is a well-established poor prognostic marker in ovarian cancer — median survival in this group is measured in weeks, not months.[2] Frequency of taps is the prognostic clock. When the interval drops to 10 days, this is the final chapter.
- 06Estimated survival <3 months: Hospice enrollment is appropriate, beneficial, and evidence-supported. All clinical thresholds above converge here. Kajiyama et al. found home/hospice death was an independent predictor of longer post-treatment survival vs. hospital death (15 vs. 9.7 weeks) — suggesting hospice itself confers benefit.[41]
- 07Patient goals have shifted to comfort and presence: When a fully informed patient — having received an honest, plain account of her prognosis — prioritizes quality of time, location of death, and symptom control over further attempts at tumor shrinkage, that is not giving up. That is clarity. Honor it.
🚨 The MBO Surgical Conversation — Say It Directly
When the bowel stops in Stage IV platinum-resistant ovarian cancer with peritoneal carcinomatosis, the family wants someone to fix it. The ER wants to scan it. The surgeon may want to cut it. But surgery in this population carries a 20–40% perioperative mortality — and the majority of survivors do not have resolution of obstruction. That is not care. The answer is: octreotide, dexamethasone, haloperidol, and a venting gastrostomy tube. Know the data. Say it directly. The family needs to hear it before the ER visit, not during the surgical consent conversation.
Out-of-the-Box Approaches
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Acupuncture
Grade BProtocol: 6–12 weekly sessions; auricular or body acupuncture; can be adapted for bed-bound patients
ACCP integrative oncology guidelines support acupuncture for pain, nausea, and fatigue in gynecologic cancer. Multiple observational studies in ovarian cancer show significant improvement in chemotherapy-related nausea (NRS reduction 1.5–2.5 points) and cancer-related fatigue. Particularly relevant for nausea associated with MBO when pharmacotherapy has limitations. Safe in anticoagulated patients using trained practitioners with appropriate needle placement considerations.[46]
Mind-Body / MBSR
Grade BProtocol: 8-week MBSR program or abbreviated 4-session format for hospice; app-based programs available for bed-bound patients
Mindfulness-based stress reduction has meaningful QoL data in advanced cancer. In ovarian cancer specifically, psychological flexibility (a core MBSR-trained capacity) is associated with lower depression, lower anxiety, and reduced cancer-related worry.[52] Particularly important given the relapse-remission psychological burden this disease imposes — by hospice, patients have experienced repeated cycles of hope and loss that require skilled psychological processing. Group-based web-delivered interventions also show effect.
Mistletoe / Iscador (Viscum album)
Grade CProtocol: Subcutaneous injections 3×/week; dose individualized; requires trained integrative oncology provider
Case report: Platinum-refractory Stage IVB ovarian cancer patient had stable disease over 42 months following mistletoe extract after stopping chemotherapy — no CA-125 progression, no new ascites.[47] Safety study in 82 breast/gynecologic cancer patients receiving Helixor VA combined with targeted therapy (PARP inhibitors, bevacizumab): no adverse safety signal (χ²=0.107, p=0.99); trend toward improved adherence.[48] QoL improvement documented in multiple gynecologic cancer observational series. Safe with current targeted therapies. Discuss with patient if interested — requires SC injection training.
Exercise / Movement Therapy
Grade BProtocol: Supervised low-intensity aerobic + resistance training; 30 min 3×/week adapted to current PS; chair-based for ECOG 2–3
Prospective cohort of advanced gynecological cancer patients: adherent integrative oncology program (≥4 treatments/6 weeks including exercise) was associated with greater 3-year overall survival vs. non-adherent (p=0.012).[46] Cancer-related fatigue and QoL both show improvement in feasibility studies in advanced ovarian cancer. Even chair-based exercise meaningfully reduces fatigue burden. Prescribe specifically — "exercise" without guidance is not actionable.
Celiac Plexus Neurolysis
Grade BProtocol: CT-guided or EUS-guided; single procedure; alcohol neurolysis; effect lasts weeks to months
For upper abdominal carcinomatosis with refractory pain, celiac plexus neurolysis reduces pain scores (WMD -0.60 vs. standard treatment) and opioid requirements (WMD -85.9 mg/day oral morphine equivalent) without survival penalty.[27] Combined celiac + superior hypogastric block provides superior pain control for patients with both upper abdominal and pelvic pain.[29] Hospice-compatible; single procedure; dramatically reduces opioid burden. Important: Combined celiac ganglia + plexus neurolysis shortens survival — use plexus neurolysis only.[28]
Indwelling Peritoneal Catheter (IPC)
Grade AProtocol: Tunneled IPC placement (PleurX or equivalent); drain 1–2L at home every 1–3 days; family trained at insertion; single outpatient procedure
Technical success 100% in case series; 76% symptom relief; 83% patient satisfaction.[15] Systematic review of 1,297 patients: 19.7% any complication; infection 4.1%, obstruction 4.4%, leakage 3.5%.[16] Transforms QoL for patients who require paracentesis more than q2wk — eliminates recurrent outpatient procedures, allows home drainage with caregiver training, and dramatically reduces burden. Discuss and place before patient is too deconditioned for an outpatient procedure. Median survival post-insertion was 19 days in one series — emphasizing the urgency of early, proactive placement.
Natural & Herbal Options
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to ovarian cancer. Patients will use supplements — this section helps you have the right conversation.
"Patients are going to use supplements whether we ask or not. The conversation is: 'I want to know what you're taking — not to judge you, but because some of these interact with your pain medications and blood thinners.' Say it plainly. Most of the time they're relieved someone asked. Ginger? Totally fine. Mistletoe? Let's talk. Curcumin on a blood thinner at end of life? No."
— Waldo, NP · Terminal2
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Ginger (Zingiber officinale) | Grade B | 250–500 mg capsule TID; ginger tea as adjunct | Nausea — highest evidence base in CINV and cancer-related nausea; 5-HT3 antagonism mechanism. Systematic review of 35 RCTs: significant reduction in grade 3 acute nausea (RR 0.19, p<0.001).[50] | Antiplatelet effect; use caution with anticoagulants. Mild CYP2C9/3A4 interaction. Avoid at doses >4g/day. Relatively safe in most hospice patients. |
| Curcumin / Turmeric | Grade C | Preclinical data only; no evidence-supported hospice dosing | Anti-inflammatory (NF-κB inhibition); in vitro ovarian cancer activity — not replicated in clinical trials. QoL benefit is theoretical, not established clinically. | Inhibits CYP3A4 and P-glycoprotein — may alter PARP inhibitor and bevacizumab levels if still on therapy. Significant anticoagulant potentiation. Avoid in patients on anticoagulation (VTE risk is already elevated in OC). |
| Mistletoe / Iscador (Viscum album) | Grade C | SC injections 3×/week; individualized dosing by trained practitioner | QoL improvement; possible disease stabilization in select cases; immunomodulation (lectin-mediated NK cell activation). Safe with PARP inhibitors and bevacizumab per observational data.[48] | No significant CYP interactions. Avoid IV use. Rare hypersensitivity reactions. Contraindicated in active autoimmune disease or organ transplant. Requires trained provider for SC injection protocol. Never present as curative. |
| Green Tea / EGCG | Grade C | 2–3 cups brewed tea daily; EGCG supplements 400–800 mg/day (limited clinical data) | Anti-proliferative signal in ovarian cancer cell lines (in vitro); modest antioxidant benefit; may reduce fatigue. Clinical trial data in ovarian cancer limited. | CYP3A4 and P-gp interactions — can alter PARP inhibitor levels. Antiplatelet effect. Caffeinated formulations — may worsen anxiety or insomnia. High-dose EGCG supplements associated with hepatotoxicity in rare cases. |
🚫 Avoid in Ovarian Cancer (Hospice Context)
- High-dose antioxidants (Vitamin C, Vitamin E): Theoretical interference with chemotherapy oxidative mechanism if patient is still on active treatment. No benefit demonstrated for comfort symptoms. Avoid pharmacologic doses.
- St. John's Wort: Potent CYP3A4 inducer — destroys PARP inhibitor and bevacizumab plasma levels if patient is still on targeted therapy. Even after stopping targeted therapy, interaction risk persists for weeks. Do not use.
- Ginkgo biloba and high-dose fish oil: Antiplatelet effects — bleeding risk in ascites and peritoneal disease context. Ginkgo specifically: avoid with any anticoagulant or antiplatelet regimen.
- Any supplement claiming direct anti-tumor activity in active peritoneal disease: CYP interaction risk is high; false hope risk is significant; no evidence base. The conversation should be: "I don't want anything interfering with your comfort medications — let's focus on what actually helps you feel better."
Timeline Guide
A guide, not a prediction. Trajectory is shaped by histology, platinum sensitivity, BRCA status, treatment response, and comorbidities.
Ovarian cancer trajectories vary more than almost any other cancer based on molecular profile. BRCA1/2-mutant patients receiving PARP inhibitor maintenance may have their initial remission extended to 3+ years. Platinum-refractory patients may survive only 3–6 months from that inflection point. Use this timeline to orient yourself to where the patient currently sits — not as a prediction, but as a clinical map. The most commonly missed window for hospice enrollment is the platinum-resistant phase, when patients appear reasonably functional but are on a trajectory that is already terminal.[37][40]
YRS–
MOS
MOS
Post-Debulking / Platinum-Sensitive / Maintenance Phase
- Post-debulking with carboplatin/paclitaxel ± bevacizumab; CA-125 declining toward nadir
- BRCA-mutant patients may be on PARP inhibitor maintenance (olaparib, niraparib) — this phase can last 1–3 years
- Performance status ECOG 0–1; functional; working, traveling, living relatively normally
- Palliative care integration should begin at this phase even though hospice is not yet appropriate — advance care planning, goals conversations, establishing relationship
- Focus: surveillance, maintenance therapy management, ACP, addressing fertility and body image grief in younger patients
MOS–
1 YR
1 YR
First/Second Platinum-Sensitive Relapse — Active Treatment / Declining
- First or second platinum-sensitive recurrence; partial responses; CA-125 trending upward between regimens
- Ascites beginning to appear; fatigue worsening; more days spent managing symptoms vs. living freely
- ECOG 1–2; still functional but treatment burden mounting
- Most commonly missed window for hospice conversation — oncologists are still treating; patient appears "okay"; but trajectory is clearly downward
- Focus: honest platinum-sensitivity prognosis conversation, advance directives, hospice as a future option to be named now
WKS–
MOS
MOS
Platinum-Resistant / Refractory — Correct Hospice Enrollment Point
- Platinum-resistant or refractory; single-agent chemo with diminishing returns; response rates <20%
- Ascites requiring paracentesis q2–4 weeks; MBO risk rising; nausea increasingly problematic
- ECOG 2–3; functional decline notable; more time in bed, reduced appetite, increasing fatigue
- This is the clinical threshold for hospice enrollment — do not wait for MBO or complete functional collapse
- Focus: comfort kit preparation, IPC placement discussion, venting gastrostomy conversation before crisis, caregiver education
DAYS–
WKS
WKS
Active Dying — Pre-Active Phase / MBO Established
- MBO established or near-complete; vomiting even with pharmacologic management if no venting tube in place
- Ascites taps every few days if no IPC; complete anorexia; minimal oral intake — sips only
- Profound fatigue; bed-bound or near bed-bound; sleeping majority of the day
- Opioid requirements escalating for peritoneal carcinomatosis pain; all medications transitioning to SQ route
- Family at high risk of crisis call — ensure comfort kit is in place and family knows exactly what to use and when
HRS–
DAYS
DAYS
Final Hours — Active Dying
- Bowel distension; all medications subcutaneous or via venting gastrostomy; no oral intake
- Cheyne-Stokes or agonal breathing; Cheyne-Stokes can be prolonged and distressing for family — prepare them specifically
- Mottling of knees and feet; perioral cyanosis; extremities cool to touch
- Unresponsive or minimally responsive; auditory awareness may persist — speak to patient as if she hears you
- Venting gastrostomy drainage may continue — explain to family that this is comfort drainage, not failure
- Presence is the primary clinical priority — the team's job at this phase is to be there and ensure the family is not alone
Medications to Anticipate
Symptom-targeted pharmacology for end-stage ovarian cancer. What to have in the comfort kit, what to titrate first, and what the evidence supports.
The dominant symptom triad in end-stage ovarian cancer is pain + nausea/vomiting + bowel obstruction. Unlike most hospice diagnoses where dyspnea drives late-phase medication needs, ovarian cancer's terminal phase is dominated by visceral, obstructive, and peritoneal symptoms. Octreotide — the most effective agent for MBO-related secretion management — is the most underused drug in this population. Haloperidol is superior to metoclopramide for obstructive nausea (metoclopramide is contraindicated in complete obstruction). Opioids for peritoneal carcinomatosis pain require subcutaneous routes as obstruction progresses. Dexamethasone serves triple duty: anti-inflammatory for MBO, appetite stimulant, and pain adjunct.[22][1]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Morphine / Hydromorphone | Opioid / Peritoneal carcinomatosis pain + visceral colic | Morphine 2.5–5 mg SQ q4h ATC + 2.5 mg PRN q1h | SQ preferred as oral route becomes unreliable with obstruction. Hydromorphone 0.5–1 mg SQ q4h if morphine poorly tolerated. Titrate 25–50% q24–48h if using ≥3 PRN doses/day.[1] |
| Octreotide | Somatostatin analogue / MBO secretion control + vomiting | 300–600 mcg/24h SQ infusion (CSCI) or 100–200 mcg SQ TID | Most important underused drug in end-stage OC. Dramatically reduces GI secretions, vomiting frequency, and abdominal distension in MBO. In Mangili 1996 series, controlled vomiting to WHO grade 0 in all 13 patients within 3 days.[22] Long-acting LAR (30 mg IM monthly) available for home management after SQ trial. ⚠ Rare: hepatic portal venous gas — reassess if pain acutely worsens |
| Haloperidol | Dopamine antagonist / MBO nausea, agitation | 1–2 mg SQ q8h; 0.5–1 mg PRN q4h | Superior to metoclopramide in bowel obstruction context. Central dopamine blockade; does not increase GI motility (unlike metoclopramide, which is contraindicated in complete MBO). Also addresses terminal agitation and delirium.[1] |
| Dexamethasone | Corticosteroid / MBO anti-inflammatory + appetite + pain adjunct | 4–8 mg SQ/IV daily (morning dosing to reduce insomnia) | Triple mechanism in OC: reduces periobstructive edema (may restore partial bowel patency), appetite stimulant (short-term), pain adjunct for carcinomatosis. Monitor glucose. Taper if using >2 weeks. Higher doses (6–16 mg) for acute MBO management.[1] |
| Hyoscine butylbromide / Glycopyrrolate | Anticholinergic / GI secretion reduction, cramping, terminal secretions | Glycopyrrolate 0.2 mg SQ q4h; or 0.6–1.2 mg/24h CSCI | Reduces GI secretions complementary to octreotide; reduces bowel colic and cramping; used for terminal secretions at end of life. Glycopyrrolate preferred over hyoscine in conscious patients — no CNS anticholinergic effects. |
| Ondansetron | 5-HT3 antagonist / Nausea adjunct | 4–8 mg PO/SQ q8h; ODT formulation for obstruction patients | Adjunctive antiemetic. Safe to use with haloperidol. ODT formulation allows oral administration even with partial obstruction. Does not increase GI motility — safe in MBO context. |
| Midazolam | Benzodiazepine / Terminal agitation, refractory symptoms | 2.5–5 mg SQ PRN; 10–30 mg/24h CSCI for continuous agitation | Terminal agitation and catastrophic symptom management. Must be in comfort kit pre-drawn and labeled before crisis. For refractory MBO distress when all other measures inadequate. Palliative sedation framework if severe refractory suffering. |
| Lorazepam | Benzodiazepine / Anxiety, dyspnea-anxiety cycle | 0.5–1 mg PO/SQ q4–6h PRN | For anxiety component of dyspnea, existential distress, anticipatory nausea. Avoid scheduled high-dose use. SL formulation available for patients who cannot swallow. |
🌿 Symptom Management Decision Tree
Evidence-based · Hospice-adaptedSelect a symptom below to begin
What is the primary symptom to address?
🚨 Ovarian Cancer Comfort Kit — Must-Haves Before Vomiting Crisis
Octreotide and haloperidol MUST be in the home before a vomiting crisis occurs. A patient with MBO vomiting feculent material at 2 AM is family trauma that could have been prevented. Do not wait for the crisis to dispense these medications. At enrollment: comfort kit should include octreotide 100 mcg/mL SQ, haloperidol 2 mg/mL SQ, morphine SQ, midazolam SQ, and glycopyrrolate SQ — all drawn and labeled. Additionally: teach the family the venting gastrostomy drainage protocol (if placed) at enrollment, not at crisis. A family who knows how to drain the tube does not call 911 at midnight.
Clinician Pointers
High-yield clinical pearls for the hospice team. The things not in the textbook — learned at the bedside over years of clinical experience.
1
The Platinum-Resistance Conversation Is the Real Conversation
Most oncologists soften it. They are not lying — but they are not saying it plain either. The hospice NP often has to be the one who says: "The chemo has stopped working the way we need it to, and the side effects are now bigger than the benefit." Say it when it is true. Say it at the platinum-resistant threshold — not after the third hospitalization for MBO. The Davidson 2021 data showed that systematic GOC conversations at this threshold reduced late chemotherapy use without reducing survival.[38]
2
Octreotide Is the Most Underused Drug in End-Stage Ovarian Cancer
If a patient with MBO does not have octreotide in the home, the comfort kit is incomplete. Octreotide reduces GI secretions, dramatically reduces vomiting frequency and volume, and allows many patients to maintain some oral hydration for weeks.[22] Long-acting LAR (30 mg IM monthly) is available for outpatient management when daily SQ is burdensome. Dispense at enrollment. Do not wait for the vomiting crisis.
3
Ascites Frequency Is the Prognostic Clock
Track it. Document it at every visit. When paracentesis interval drops from every 3 weeks to every 10 days, this is the final chapter. Median survival after first paracentesis in ovarian cancer is 81 days — significantly longer than other cancers — but when frequency accelerates, the trajectory changes rapidly.[2] Use this to time IPC placement conversations, medication escalation, and family preparation. Do not be caught off-guard by this transition.
4
Surgery for MBO at This Stage Kills — Know the Data, Redirect Firmly
In patients with Stage IV platinum-resistant ovarian cancer and peritoneal carcinomatosis who present with MBO, surgical intervention carries a 20–40% perioperative mortality — and the majority of survivors do not have resolution of obstruction.[20] When the family, ER, or surgeon raises surgical options, you need to be ready to say: "In her specific situation, surgery has a one-in-four chance of killing her on the table, and most patients who survive don't actually get better from it. The medical management — octreotide, dexamethasone, haloperidol, and a venting tube — is the right answer for her."
5
IPC Placement Transforms QoL — Advocate for It Before the Patient Is Too Deconditioned
Indwelling peritoneal catheters eliminate the burden of recurrent paracentesis visits for patients who are tapping q2wk or more frequently. Family can be trained to drain 1–2L at home every 1–3 days. The window to place it is narrow — once ECOG reaches 3–4, outpatient procedures become impractical. In one case series, median survival after IPC insertion was 19 days — meaning many patients were referred too late.[15] Bring up IPC at the platinum-resistant transition point. Place it before you need to.
6
Caregiver Fatigue — Assess It at Every Visit as a Separate Urgent Problem
The caregiver of a woman with end-stage ovarian cancer is managing ascites drainage, MBO vomiting, pain crises, and profound physical deterioration over weeks to months. Caregiver burnout in gynecologic cancer is well-documented and severe. Ask directly at every visit: "How are YOU doing? Not her — you." Give them permission to accept respite. Document caregiver distress as a clinical problem. A burned-out caregiver cannot safely manage a comfort kit at 3 AM.
"When the bowel stops, the family wants someone to fix it. The ER wants to scan it. The surgeon wants to cut it. But at Stage IV platinum-resistant ovarian cancer with carcinomatosis, surgery gives you a 22% chance of dying on the table and the rest of the patients don't get better. That's not care. Octreotide, dexamethasone, haloperidol, and a venting tube. That's the answer."
— Waldo, NP · Terminal2
Psychosocial & Spiritual Care
Existential distress, relapse-remission trauma, body image, BRCA guilt, and goals-of-care communication. The symptom burden you can't see on a vitals sheet.
Ovarian cancer imposes a psychosocial burden unlike most other diagnoses. It threatens womanhood, fertility, body image, and relationships. The relapsing-remitting trajectory — treatment, hope, response, recurrence, repeat — creates repeated cycles of hope and grief that leave patients, by end stage, carrying the psychological weight of years of failed treatment. One study traced the healthcare journeys of women with advanced gynecologic cancer and found wild, arbitrary variation in whether anyone ever had the real conversation with them.[42] By hospice enrollment, most have not received adequate psychosocial support. That gap is the hospice team's responsibility to close.
Relapse-Remission Trauma
Grade BRepeated cycles of hope and loss across 3–7 years of treatment create a form of psychological exhaustion that is distinct from simple depression. Patients have had complete remissions — they have been told "no evidence of disease" — and then watched the cancer return. By hospice, they have typically endured 4–6 lines of therapy and know the pattern. Acknowledge this exhaustion directly: "You have been fighting this for a very long time. It is okay to be tired." Psychological flexibility (acceptance and commitment therapy principles) reduces depression and anxiety in OC survivors.[52] Referral to psychology, social work, and chaplaincy at enrollment — not at crisis.
Diagnostic Delay Grief
Many women with ovarian cancer were told for months or years that their symptoms — bloating, pelvic pressure, urinary frequency, fatigue — were IBS, anxiety, normal aging, or perimenopause. When the correct diagnosis was finally made, it was already Stage III or IV. This history produces specific grief and anger: anger at the system, anger at clinicians, grief about time lost. Acknowledge it: "You weren't listened to for a long time. That was wrong. I want you to know that we are listening now." Do not minimize or rationalize the delay. Honor the grief.
Fertility and Womanhood
For women diagnosed in their reproductive years, the loss of ovaries and reproductive capacity represents a profound grief that often sits beneath the terminal diagnosis without being named. Do not assume it has been adequately processed. Ask: "How have you felt about the changes this disease has brought to your body and your sense of yourself?" This opens a conversation that may have been closed for years. For women of any age, oophorectomy changes the relationship with womanhood and body identity — this is a legitimate psychological loss deserving direct clinical attention.
BRCA Guilt and Family Burden
Patients with germline BRCA1/2 mutations often carry guilt about what they may have passed to their daughters and sons. This guilt is a real psychological burden that may be invisible unless you ask. "Has it been on your mind that your daughters might carry this mutation?" — followed by: "That information can protect them. Getting them tested is one of the most powerful things that can come from your experience. It is a gift, not a curse." Ensure genetic counseling referral for family members is documented and not left to the patient alone to execute.
Body Image and Ascites Distension
Malignant ascites causes visible abdominal distension that many patients find deeply humiliating — they describe looking "9 months pregnant" when they have not eaten in days. Address this with clinical directness and compassion: "The swelling you see is fluid that the cancer is causing. It is not you gaining weight. It is not from eating. We are treating it, and we will keep treating it." Offer specific help with clothing, positioning, and IPC placement to restore a sense of body control. Do not ignore the visible physical reality of this disease.
Goals-of-Care Framing
A common operative goal in this population is: "I don't want to die with a tube in my stomach." That specific statement — about a feeding tube, a NG tube, an IV line — often reflects something much larger: a desire for dignity, for natural death, for presence over intervention. Hear the specific words and reflect them back: "It sounds like what matters most to you is being comfortable and not having things done that won't really help you. Is that right?" Then build the care plan around it. The goals-of-care conversation in OC is not about "giving up" — it is about finally having control over a disease that has controlled the patient for years.
Clinical Pearl — Spiritual Opening
"What gives you strength during this time?" opens spiritual conversation without assuming religious tradition. For women who have watched their bodies fight and fail repeatedly — who have had remissions and relapses across years — the spiritual question is often about meaning, legacy, and whether their suffering has mattered. Faith communities may be a source of strength or a source of complicated grief (around illness as punishment, around medical decision-making). Ask without assumption. Refer to chaplaincy at enrollment, not at the moment of active dying.
Family Guide
Plain language for families. Share, print, or read aloud at the bedside.
Watching someone you love with ovarian cancer is one of the hardest things a family can do. This disease is visible — the abdomen swells, the appetite disappears, the bowel may stop working. It can be frightening to watch, and it can feel impossible to know how to help. You are not helpless. Your presence — staying close, speaking softly, holding her hand — is the most powerful medicine we have at this stage. You do not need to fix it. You need to be there.
What You May See
- Abdominal swelling: The belly grows larger as fluid builds up (ascites). This is caused by the cancer, not by eating. We drain it regularly to provide comfort — and can place a catheter so this can be done at home.
- Nausea and vomiting: The bowel may slow down or partially stop. Medications (especially octreotide) can dramatically reduce nausea and vomiting. Call us if vomiting becomes severe or uncontrolled.
- Loss of appetite: The body is no longer using food the same way it used to. This is the cancer — not starvation. Do not push eating. Small sips and bites are enough. Forcing food causes suffering, not strength.
- Severe fatigue: She may sleep most of the day. This is the disease, not depression. Rest is appropriate and healing. Quiet presence is more important than conversation.
- Abdominal and pelvic pain: Pain is managed with medications that we will adjust regularly. Tell us if pain is not controlled between visits.
- Changes in bowel pattern: Constipation, then sometimes no bowel movements at all as the disease advances. We anticipate this and manage it with medications and procedures.
- Breathing changes: Fluid in the belly can press on the breathing muscles. Draining fluid often helps breathing. Later, breathing may become slower or irregular — this is a normal part of the dying process.
How You Can Help
- Don't push food or fluids: At this stage, the body is winding down. Small sips or bites when she asks are perfect. Mouth swabs keep lips and mouth comfortable. Forcing eating causes distress, not healing.
- Help with IPC drainage: If she has a peritoneal drain (tube in her belly), we will teach you exactly how to use it. Draining regularly at home — 1–2 liters — prevents the discomfort of fluid buildup and reduces ER trips.
- Elevate the head of the bed: Keep the head of the bed raised 30–45 degrees. This reduces abdominal pressure, improves breathing comfort, and decreases nausea.
- Report severe vomiting immediately: If vomiting is continuous, uncontrolled, or looks or smells unusual (dark, foul-smelling), call us right away — this is a symptom we can treat.
- Give medications as prescribed: Pain, nausea, and agitation medications at the bedside are there for a reason. Give them when needed. You will not cause harm by using them as directed — you will prevent suffering.
- Be present without needing to fix anything: Your presence is the treatment. Silence is okay. Touch is powerful. Reading aloud, playing favorite music, telling her what she means to you — all of this matters, even in the final days.
- Take care of yourself: You cannot pour from an empty cup. Accept help when offered. Call us when you need support — not just when she does.
📞 Call the Nurse Immediately If You See:
Vomiting that won't stop despite medications, especially if it is dark, foul-smelling, or in large amounts — this may mean the bowel is completely obstructed and we need to respond immediately. Sudden severe abdominal pain or hardness of the abdomen (rigid, board-like) — this requires urgent assessment. Inability to wake her or rouse her when you would normally expect her to respond. IPC (peritoneal drain) drainage that has suddenly stopped, is pulling out, or shows blood or cloudy fluid that looks infected. Any sudden change in breathing pattern, skin color, or level of consciousness.
🙏 What you have done for her is extraordinary. You have been her advocates, her caregivers, her witnesses through one of the hardest journeys in medicine. You are not failing her by moving to comfort care. You are fulfilling the deepest promise of love — to stay present, relieve suffering, and not let her be alone. That is everything.
Waldo's Top 10 Tips
Clinical field wisdom from 12+ years at the bedside — specific to ovarian cancer. The things you learn after doing this long enough. Not guidelines — real.
-
01Say the platinum-resistance thing plainly — and say it when it's true, not after the third hospitalization. The platinum-sensitivity conversation is the most important moment in the disease trajectory, and most oncologists soften it. They say "we're going to try something different" instead of "the chemotherapy has stopped working in a way that meaningfully helps you." As the hospice NP, you may be the first person to say it clearly. Say it at the platinum-resistant threshold. Not after MBO, not after the ER visit, not after she's lost 30 pounds. That conversation needs to happen when she's still strong enough to make real decisions with it.
-
02Octreotide changes everything in MBO — and it should be in the home before the crisis, not after. I have seen families watch their mother vomit for three days waiting for someone to order octreotide. It is the most underused drug in this disease. When you enroll a patient with advanced ovarian cancer, put octreotide in the comfort kit as a standard item — not a reactive one. 300–600 mcg/24h subcutaneous. When the bowel slows or stops, that medication is already there. The family doesn't call 911. The patient doesn't go to the ER. That's the goal.
-
03Ascites frequency is the prognostic clock — track it at every visit, not just when you're worried. First paracentesis: write the date. Current interval: document it. When the interval drops from q3wk to q10d — write it. When it drops to q7d — that is the final chapter, and the family needs to know that even if they don't know the words "prognostic clock." That shift is your signal to escalate comfort preparations, have the bedside death conversation, and ensure the venting tube discussion has happened. Don't get caught off guard by an interval you weren't tracking.
-
04Surgery for MBO at end-stage kills — know the data, and redirect with confidence, not apology. Twenty to forty percent perioperative mortality in platinum-resistant OC with carcinomatosis.[20] Most who survive do not have resolution. When the ER calls you and says the surgeon wants to do a bowel resection, you need to be ready to say: "In her specific situation — Stage IV, platinum-resistant, peritoneal carcinomatosis — that surgery carries a one-in-four chance of killing her on the table and most patients who survive don't get better. We have a medical protocol that works. Octreotide, dexamethasone, haloperidol, venting tube. That is the right answer for her." You are not being negative. You are being correct.
-
05Advocate for IPC placement before the patient is too deconditioned to tolerate an outpatient procedure. The indwelling peritoneal catheter is a transformational quality-of-life intervention for patients who are tapping every two weeks or more. Family drains 1–2 liters at home. No more twice-monthly outpatient appointments when she can barely get out of bed. No more rushing to the procedure center in pain. The window is narrow — once she's ECOG 3–4, you've missed it. Bring it up at the platinum-resistant transition. I've never had a patient regret the IPC. I've had plenty whose families said "why didn't we do this sooner?"
-
06Relapse-remission exhaustion is real — acknowledge it clinically, not just sympathetically. By the time a woman with ovarian cancer arrives on hospice, she has been through 4–6 lines of chemotherapy, multiple surgical procedures, and years of partial responses followed by progression. She has had "no evidence of disease" conversations and "we found something on the scan" conversations more times than she can count. That psychological pattern creates an exhaustion that is distinct from depression and different from the grief of a new diagnosis. Say: "You have been fighting this for a very long time. It is okay to be tired. It is okay to want to stop. That is not giving up — that is wisdom." Mean it when you say it.
-
07BRCA family genetic counseling at hospice enrollment is a clinical obligation — not optional, not "someone else's job." If your patient carries a BRCA1/2 germline mutation, her daughters have a 50% chance of carrying it — and a 40%+ lifetime ovarian cancer risk if they do. This is actionable information that can save lives. At enrollment: ask if the patient has shared her BRCA status with adult children. Document the answer. Offer to provide a referral letter or contact for the surviving family members. If the patient is too ill to manage this conversation herself, document that you've offered and note who should receive follow-up. This is the hospice NP's moment to leave a gift that outlasts the patient's death.
-
08Body image and ascites distension — address it directly, not around the edges. Malignant ascites in ovarian cancer causes visible abdominal distension that patients describe as humiliating. They look pregnant when they have not eaten in days. Families focus on the belly. Clinicians talk around it. Say it plainly: "The swelling is fluid that the cancer is producing. It is not weight gain. It is not something you ate. We are managing it, and we can place a tube so it's managed at home." Then help her with IPC placement, with clothing adjustments, with positioning. Give her back some control over her own body. That is as therapeutic as any medication.
-
09Younger patients have different grief, different goals, and different conversations — don't use the same script. A 42-year-old woman with ovarian cancer who leaves behind young children is not having the same end-of-life experience as a 72-year-old. She has different losses (fertility, career, watching her children grow), different fears (her children's futures, who will raise them), and different unfinished business. Her spiritual questions are different. Her goals-of-care priorities are different. Slow down. Ask what she most needs to do or say or leave behind before she dies. Help her accomplish those things. The clinical skills are the same; the conversation is entirely different.
-
10Caregiver fatigue in ovarian cancer is severe — assess it as a separate clinical obligation at every visit. This disease has been present in the household for years. The caregiver has been a nurse, a pharmacist, a chauffeur, an advocate, and an emotional container for a very long time before hospice arrived. By enrollment, many are already burned out beyond what they show you. Ask directly, every visit: "How are YOU doing — not her, you?" Give them specific permission to accept respite care. Refer them to caregiver support resources. Document caregiver distress as a clinical problem with a plan. A caregiver who collapses at 3 AM cannot operate an octreotide infusion. Caregiver health is patient safety.
— Waldo, NP
References
Peer-reviewed citations sourced from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
1
Miller D, Nevadunsky N. Palliative Care and Symptom Management for Women with Advanced Ovarian Cancer. Hematol Oncol Clin North Am. 2018;32(6):1087–1102.
2
Fridegren J, Björkhem-Bergman L, Schultz T, Strang P. Ascites as a Predictive Factor in Malignancies in the Last Year of Life. J Palliat Med. 2024;28(1):35–41.
3
Kietpeerakool C, et al. Management of drainage for malignant ascites in gynaecological cancer. Cochrane Database Syst Rev. 2019;(12):CD007794.
4
Harding V, et al. Safety, cost-effectiveness and feasibility of daycase paracentesis. Br J Cancer. 2012;107(6):925–930.
5
Decruze SB, et al. Paracentesis in ovarian cancer: a study of the physiology during free drainage. J Palliat Med. 2010;13(3):251–254.
6
Macdonald R, et al. Ovarian cancer and ascites: A questionnaire on current management in the UK. J Palliat Med. 2006;9(6):1264–1270.
7
Gu X, et al. Management of non-ovarian cancer malignant ascites through indwelling catheter drainage. BMC Palliat Care. 2016;15:44.
8
Saada E, et al. Pathogenesis and management of refractory malignant ascites. Bull Cancer. 2011;98(6):679–687.
9
Bodisch A, et al. Methods of symptom control in malignant ascites. Wien Med Wochenschr. 2008;158(23–24):687–694.
10
Ramirez I, et al. Peritoneal catheter site metastasis in a patient with advanced ovarian cancer. Am J Hosp Palliat Care. 2011;29(3):241–242.
11
Sartori S, et al. Intracavitary recombinant interferon alpha-2b for malignant peritoneal effusions. Oncology. 2001;61(3):192–196.
12
Iyengar TD, Herzog TJ. Management of symptomatic ascites using the PleurX catheter. Am J Hosp Palliat Care. 2002;19(1):35–38.
13
Varshney H, Sirohiya P. A Novel Technique for Indwelling Pigtail Catheter Placement in Ovarian Carcinoma. J Pain Palliat Care Pharmacother. 2025;39(4):584–586.
14
Simas D, et al. Long-Term Abdominal Drains as a Therapeutic Option in Refractory Ascites — Systematic Review. GE Port J Gastroenterol. 2025;32(4):227–241.
15
Murray FR, et al. Permanent Tunneled Drainage of Ascites in Palliative Patients: Timing Needs Evaluation. J Palliat Med. 2022;25(7):1132–1135.
16
Stukan M. Drainage of malignant ascites: patient selection and perspectives. Cancer Manag Res. 2017;9:115–130.
17
Riedel AN, et al. Prognosis of patients with ascites after PleurX insertion. Scand J Gastroenterol. 2018;53(3):340–344.
18
Solbach P, et al. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter. Eur J Gastroenterol Hepatol. 2017;29(5):539–546.
19
Jansen J, et al. Bowel obstruction in advanced tubo-ovarian cancer: a retrospective cohort study. Ann Med Surg. 2023;85(5):1539–1545.
20
Kucukmetin A, et al. Palliative surgery versus medical management for bowel obstruction in ovarian cancer. Cochrane Database Syst Rev. 2010;(7):CD007792.
21
Mangili G, et al. Palliative care for intestinal obstruction in recurrent ovarian cancer: a multivariate analysis. Int J Gynecol Cancer. 2005;15(5):830–835.
22
Mangili G, et al. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996;61(3):345–348.
23
Matulonis UA, et al. Long-acting octreotide for treatment and symptomatic relief of bowel obstruction. J Pain Symptom Manage. 2005;30(6):563–569.
24
Thampy S, et al. Safety and Efficacy of Venting Gastrostomy in Malignant Bowel Obstruction. J Palliat Care. 2019;35(2):93–102.
25
Maeda I, et al. Hepatic portal venous gas: a rare complication of MBO during octreotide. J Pain Symptom Manage. 2013;47(2):e2–5.
26
Birthi P, Sloan P. Interventional treatment of refractory cancer pain. Cancer J. 2013;19(5):390–396.
27
Yan BM, Myers RP. Neurolytic celiac plexus block for pain control in unresectable pancreatic cancer. Am J Gastroenterol. 2006;102(2):430–438.
28
Levy MJ, et al. Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival. Clin Gastroenterol Hepatol. 2019;17(4):728–738.
29
Huang L, et al. Combined neurolytic block of celiac and superior hypogastric plexuses for upper abdominal cancer pain. J BUON. 2014;19(3):826–830.
30
Shwita AH, et al. Retrocrural Celiac Plexus Block vs. Splanchnic Nerve Block for upper GIT tumors. Korean J Pain. 2015;28(1):22–31.
31
Bertolaccini L, et al. Malignant pleural effusions: review of treatment and our experience. Rev Recent Clin Trials. 2007;2(1):21–25.
32
Filosso PL, et al. Preliminary results of a new small-bore percutaneous pleural catheter for MPEs. Eur J Surg Oncol. 2011;37(12):1093–1098.
33
Barnes H, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease. Cochrane Database Syst Rev. 2016;(3):CD011008.
34
Arrieta O, et al. Mirtazapine as Appetite Stimulant in NSCLC and Anorexia. JAMA Oncol. 2024;10(3):305–314.
35
Kasvis P, Vigano ML, Vigano A. Health-related quality of life across cancer cachexia stages. Ann Palliat Med. 2018;8(1):33–42.
36
Ruiz Garcia V, et al. Megestrol acetate for treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev. 2013;(3):CD004310.
37
Corrado G, et al. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther. 2017;17(12):1147–1158.
38
Davidson BA, et al. Promoting timely goals of care conversations in gynecologic cancer. Gynecol Oncol. 2021;164(2):288–294.
39
von Gruenigen VE, et al. Quality of life and care needs in platinum-resistant ovarian cancer. Gynecol Oncol. 2018;150(1):119–126.
40
Palaia I, et al. EOLO Study: Approach to Ovarian Cancer Patients at the End of Life. Oncology. 2019;97(5):306–310.
41
Kajiyama H, et al. Survival after Anticancer Treatment of Terminally Ill Patients with Ovarian Carcinoma. J Palliat Med. 2020;23(8):1060–1065.
42
Dillon EC, et al. The Healthcare Journey of Women With Advanced Gynecological Cancer. Am J Hosp Palliat Care. 2022;39(9):1090–1097.
43
Stevens EE, Abrahm JL. Adding Silver to the Rainbow: Palliative and EOL Care for the Geriatric LGBTQ Patient. J Palliat Med. 2018;22(5):602–606.
44
Gadducci A, et al. Treatment options in patients with recurrent ovarian cancer. Anticancer Res. 2001;21(5):3557–3564.
45
Gibbs DD, Gore ME. Pursuit of optimum outcomes in ovarian cancer: methodological approaches to therapy. Drugs. 2001;61(8):1103–1120.
46
Segev Y, et al. Correlation between integrative oncology treatment program and survival in advanced gynecological cancer. Support Care Cancer. 2021;29(7):4055–4064.
47
Hwang WY, et al. Prolonged stabilization of platinum-refractory ovarian cancer with long-term mistletoe extract treatment. Medicine (Baltimore). 2019;98(8):e14536.
48
Schad F, Thronicke A. Safety of Combined Targeted and Helixor L. Therapy in Breast and Gynecological Cancer. Int J Environ Res Public Health. 2023;20(3).
49
Schad F, et al. Evaluation of QoL in Lung Cancer Patients Receiving Radiation and Viscum album L. Radiat Oncol. 2023;18(1):47.
50
Lin CY, et al. Efficacy and Safety of Ginger on Chemotherapy-Induced Nausea and Vomiting: Systematic Review and Meta-analysis. Cancer Nurs. 2024;48(6):455–466.
51
Zhuang Y, et al. Effect of ginger-partitioned moxibustion combined with ringheaded thumb-tack needle stimulation on gastrointestinal reactions during chemotherapy. Zhen Ci Yan Jiu. 2024;49(7):700–706.
52
Telles R, et al. Psychological flexibility, distress, and coping in ovarian cancer survivors. J Psychosoc Oncol. 2025:1–18.
53
Powell MF. Healing through Palliative Care. J Palliat Med. 2019;22(5):595–596.
54
Balink H, et al. Repetitive phosphorus-32 peritoneal instillations for malignant ascites. Clin Nucl Med. 2003;28(7):545–547.
55
Bevan J, et al. Permanent catheter drainage system for palliation of diuretic-resistant ascites. ESC Heart Fail. 2015;3(1):60–62.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Private Notes
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.